Program to help patients with long-term COVID-19 symptoms
Covid-19 Long Haul Syndrome: Undiagnosed Disorder Post Covid-19 Alternative Treatment Study.
This study is testing a program to help people with long-term COVID-19 symptoms by offering treatments and support to see if it can improve their health.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Well- Konnect Healthcare Services and Research Firm Research network |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT06441955 on ClinicalTrials.gov |
What this trial studies
This program focuses on understanding and treating the long-term effects of COVID-19, specifically targeting individuals who have experienced persistent symptoms after their initial infection. It aims to recruit 25 to 100 participants who have tested positive for COVID-19, regardless of their treatment history. The study will involve comprehensive assessments and provide various interventions, including medications and behavioral therapies, to address the core symptoms associated with long-haul COVID-19. Additionally, the program emphasizes diversity in participant recruitment to ensure a wide representation of demographics.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have tested positive for COVID-19 and are experiencing persistent symptoms.
Not a fit: Patients with a history of myocarditis, pericarditis, or severe renal impairment may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life for patients suffering from long-haul COVID-19 symptoms.
How similar studies have performed: Other studies have explored treatments for long-haul COVID-19, but this program's comprehensive approach and focus on diverse biomarker categories may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion of Men, Women, and Minorities * Participants must be at least 18 years old. * Participants must have a positive COVID-19 diagnosis or clinical diagnosis of COVID-19 * Participants must have experienced persistent symptoms after recovering from the acute phase of the illness. * Participants must be willing to provide informed consent to participate in the study. * Participants must be able to communicate effectively in English or have a translator available. * Participants must be able to attend follow-up appointments as required by the study protocol. * Participants must not have any medical conditions or take any medications that could interfere with the study results. Exclusion Criteria: * \>18 years of age * Medical History of Myocarditis * Medical History of Pericarditis * Medical History of Severe renal impairment (eGFR \<30 mL/min).
Where this trial is running
Bethesda, Maryland
- NIH Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Kawana J Williams, Ph.D. — The National Institute of Health All of Us Research Program At Well-Konnect Healthcare Services and Research Center
- Study coordinator: Kawana J Williams, Ph.D.
- Email: Kawana.williams@waldenu.edu
- Phone: 2406201587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.